We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Hyperion’s Ravicti for Chronic Management of Some Urea Cycle Disorders
FDA Approves Hyperion’s Ravicti for Chronic Management of Some Urea Cycle Disorders
February 1, 2013
The FDA has approved Hyperion’s orphan drug Ravicti for the chronic management of some urea cycle disorders (UCD) in patients ages 2 and older.